Apyx Medical's branded AYON push offsets sharp OEM drop, holds full-year sales outlook
The US device maker kept its 2026 sales range intact, trimmed planned spending and began rolling out a new AYON liposuction handpiece after a quarter of uneven segment results.
Apyx Medical Corp posted third-quarter 2026 revenue of $14.0 million, up 9%, in results published on 5 November. The company credited its AYON body contouring system for the increase.
The segment split was stark. Surgical Aesthetics, the unit that sells under the company's own brand, grew 17% on AYON demand, while the OEM segment shrank 42%. The material reviewed gives no dollar figures for either unit, so the size of the offset to group revenue cannot be stated.
Apyx has also begun a full commercial launch of the AYON power liposuction handpiece, which won FDA clearance earlier this year. The available information does not specify the clearance pathway, launch timing or any pricing for the accessory.
Management reaffirmed its 2026 revenue guidance of $59 million to $60 million and lowered its operating expense outlook. No further detail on the size of the spending reduction, profitability or cash position was available.
Why it matters
- Growth is coming from Apyx's own branded systems, while the OEM business is contracting sharply, shifting the revenue mix.
- The $59-60 million revenue guidance is unchanged, but the lower operating expense outlook changes the cost side of the picture.
- The handpiece launch extends the AYON line, though no sales expectations for it were disclosed.
- A wider commercial footprint also makes post-market surveillance and complaint handling more relevant for the product family.
Company's press release (SEC filing): Apyx Medical Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
